Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 31467191.
- Also identified by DOI 10.1136/thoraxjnl-2019-213522.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this investigation was to elucidate the effect of CPAP withdrawal on neurometabolic and cardiometabolic markers in patients with obstructive sleep apnoea. We evaluated 70 patients (mean age 61±10 years, 82% men) treated with CPAP in two 2-week, parallel, randomised controlled trials. CPAP withdrawal resulted in elevated 3,4-dihydroxyphenylglycol, norepinephrine and cortisol after 2 weeks of CPAP withdrawal; however, no statistically significant changes of the renin-angiotensin-aldosterone system (RAAS) determinants were documented. In summary, CPAP withdrawal may be more prominently linked to short-term increases in sympathetic activation than hypothalamic-pituitary-adrenal axis or RAAS activation. ClinicalTrials.gov Identifier: NCT02493673 and NCT02050425.
Medical subject headings
- Continuous Positive Airway Pressure
- Hydrocortisone
- Methoxyhydroxyphenylglycol
- Norepinephrine
- Sleep Apnea, Obstructive